Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-20

Clinical Trial Update: Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating responses to vaccination with Shigella vaccine CVD 30000 has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Shigella vaccine CVD 30000

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Shigella | Phase 2 | Status: COMPLETED | Results posted: 2024-05-20